Search
Menu
Home
HTB
2022
April
HTB
April 2022
Contents
Editorial
HTB April 2022 (1 April 2022)
Conference reports
29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): second reports
CROI 2022: Webcasts now online and open access
CROI 2022: Islatravir studies for HIV treatment and PrEP
CROI 2022: UK study reports diabetes mellitus in 9% of HIV positive Africans in the UK on stable ART
CROI 2022: Life expectancy reduced by eight years following hospitalisation for a mental health condition in South Africa
CROI 2022: Long COVID persists for over a year: evidence for divergent immune responses
CROI 2022: Risk factors for NAFLD and proteinuria in HIV positive people on ART in the REPRIEVE study
CROI 2022: UK study shows PEP is started earlier using home starter packs
CROI 2022: Summary of 14 key studies on HIV and liver disease
CROI 2022: Genomic entrapment of HIV in people on long-term ART, chimeric antigen receptor T cells and more on bNAbs
Antiretrovirals
US FDA removes need for oral lead-in with long-acting cabotegravir/rilpivirine injections: indication expanded to adolescents
HIV prevention and transmission
HIV vaccine study using mRNA technology starts in the US
South Africa approves dapivirine vaginal ring for HIV prevention
COVID-19: HIV and COVID-19 coinfection
BHIVA statement on fourth vaccine dose for people living with HIV in the UK
COVID-19: vaccine research
Temporary protection against omicron needs mRNA booster: limited data for those at highest risk
PDFs
HTB: no. 4 (1 April 2022) PDF downloads
HTB RSS
Early access
Lenacapavir submitted to the US FDA with an indication for HIV PrEP
20 December 2024
i-Base guides updated online
5 December 2024
All early access reports
Current issues
December 2024
November 2024
October 2024
Back issues
Special report
Unheard: The medical practice of silencing – by Dr Rageshri Dhairyawan
9 November 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate